Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.04 | 0.04 | -0.13 |
| FCF Yield | 9.42% | 10.06% | 6.75% | 9.19% |
| EV / EBITDA | 15.89 | 29.14 | -48.47 | 32.01 |
| Quality | ||||
| ROIC | 1.78% | 1.01% | -1.00% | 0.74% |
| Gross Margin | 34.91% | 27.34% | 33.43% | 29.45% |
| Cash Conversion Ratio | – | 3.47 | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -4.89% | -6.81% | -9.68% | -8.58% |
| Free Cash Flow Growth | -7.59% | 48.17% | -23.60% | 14.69% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 4.23 | -9.89 | 5.29 |
| Interest Coverage | 17.42 | 7.97 | -5.29 | 3.88 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.20 | 0.15 | 0.15 |
| Cash Conversion Cycle | 513.07 | 507.58 | 663.30 | 640.95 |